help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

Published ahead of print on April 25, 2008
Am. J. Respir. Cell Mol. Biol. 2008, doi:10.1165/rcmb.2008-0109TR
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Janssen, L. J
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janssen, L. J

Submitted on March 19, 2008
Revised on April 23, 2008

Isoprostanes and Lung Vascular Pathology

Luke J Janssen1*

1 Department of Medicine, Firestone Institute for Respiratory Health, St. Joseph's Hospital, and McMaster University, Hamilton, Ontario, Canada

* To whom correspondence should be addressed. E-mail: janssenl{at}mcmaster.ca.

Isoprostanes are products of peroxidative attack of membrane lipids. As such, they accumulate to substantial levels in conditions of oxidative stress, including many pulmonary vascular diseases such as acute lung injury and pulmonary hypertension, and are increasingly being used as indicators of disease state and severity. However, our group and others have hypothesized that they are more than inert markers, but may also act as signal transduction molecules. As isomers of prostaglandins, they can exert powerful biological effects on many lung cell types through actions on prostanoid receptors. In this review, we collect many lines of evidence which point to causal roles for the isoprostanes in those disease states.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2008 American Thoracic Society.